Benefit of OTC Formula Against COVID-19-Statistical Analysis Explained.

Abstract

“Our adoption of conservative exposure-and-symptom-presentation values in data analysis may compensate for lacunae in study design and execution. The study emerged from our efforts to protect our patients and staff members from COVID-19 [in the time-frame March-July 2020, when no or very limited effective guidelines or treatments were available]...it is our hope that the study will serve as a basis for future larger-scale studies of enhanced design...While we believe that the stark difference in clinical outcomes between the test and control groups demonstrates the utility of the study formulations, we certainly welcome future extensive prospective studies.”